地诺孕素在子宫内膜异位症不孕患者中的应用研究进展  

Application of dienogest in infertile patients with endometriosis

作　　者：王迎曦 王丽娜[1] 李蓉[1] 甄秀梅[1] Wang Yingxi;Wang Lina;Li Rong;Zhen Xiumei(Reproductive Medicine Center,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院生殖医学中心,北京100191

出　　处：《中华生殖与避孕杂志》2025年第2期202-206,共5页Chinese Journal of Reproduction and Contraception

基　　金：国家重点研发项目(2022YFC2703800)。

摘　　要：相较于传统促性腺激素释放激素类似物,地诺孕素具有不良反应低、成本效益高及改善生活质量的优势。本文综述了地诺孕素在治疗子宫内膜异位症及相关不孕症中的临床应用,探讨了其作为合成孕激素的治疗机制,包括抑制病灶生长和控制局部炎症反应,以减轻症状和对卵巢功能进行保护以改善生育预后。未来研究需进一步验证地诺孕素在辅助生殖技术中应用的效果及安全性,为子宫内膜异位症合并不孕症患者提供更有效的治疗选择。Compared with traditional gonadotropin-releasing hormone analogues,dienogest demonstrates several advantages,including a more favorable side effect profile,enhanced cost-effectiveness,and improved quality of life for patients.This article provides a comprehensive review of the clinical applications of dienogest in the management of endometriosis and its associated infertility.It explores the drug's mechanisms of action as a synthetic progestin,including its ability to inhibit the growth of endometriosis lesions and modulate local inflammatory responses,thereby alleviating symptoms and preserve ovarian function to enhance fertility outcomes.Future research should focus on validating the efficacy and safety of dienogest within assisted reproductive technology,ultimately providing more effective therapeutic options for individuals facing endometriosis-related infertility.

关 键 词：子宫内膜异位症 不孕症 生殖技术 辅助 地诺孕素 

分 类 号：R711.71[医药卫生—妇产科学]